ReviewExpert review of pharmacoeconomics & outcomes research2011
Health-related quality of life in ovarian cancer patients and its impact on clinical management.
Review in Expert review of pharmacoeconomics & outcomes research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Proactive use of PROMs in ovarian cancer survivors: a systematic review.Journal of ovarian research · 2019Pooled it
- Trial
- Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2021Trial
- Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.The Lancet. Oncology · 2013Trial
- Towards personalised follow-up care in ovarian cancer using online remote PROMs monitoring: a study protocol of a feasibility trial.BMJ open · 2026Article
- Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer.Targeted oncology · 2026Observational
- Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina.PharmacoEconomics - open · 2024Article
- Health state utility and health-related quality of life measures in patients with advanced ovarian cancer.Gynecologic oncology reports · 2023Article
- Mental health disorders among ovarian cancer survivors in a population-based cohort.Cancer medicine · 2023Article
- Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.Patient related outcome measures · 2023Review
- Where is ERAS in the management of advanced ovarian cancer?: between myths and truths.Journal of gynecologic oncology · 2022Article
- Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Review
- Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study.Journal of clinical medicine · 2021Article
- The implementation of enhanced recovery after surgery protocols in ovarian malignancy surgery.Gland surgery · 2021Review
- Women Diagnosed with Ovarian Cancer: Patient and Carer Experiences and Perspectives.Patient related outcome measures · 2021Article
- Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Although the incidence of ovarian cancer is less than that of other female cancers, the morbidity and mortality associated with the disease course is high. Because treatment involves radical surgery and intense courses of chemotherapy, health-related quality of life (HRQOL) is often compromised. Most patients recur post-first-line therapy and undergo multiple rounds of chemotherapy. Thus, HRQOL is further disrupted. As the ongoing search for optimal therapies in both the first-line and recurrent setting continues, much attention is paid towards clinical trial design and implementation. Over the last decade, patient-reported outcomes and HRQOL measurement have become an integral part of these trials. HRQOL data are valued in examining the extent of treatment benefit and therefore can aid in decision-making during active treatment and palliative care. HRQOL and patient-reported outcome measurement is also useful in determining symptom prevalence, severity and management. This article highlights the state of the science of HRQOL measurement in clinical trial design and outcomes. In addition, symptom management in ovarian cancer and its ability to modulate quality of life will be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.